Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Annals of the American Thoracic Society|October 27, 2020
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACTMark T Dransfield, Courtney Crim, Gerard J Criner, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Pragmatic and Observational Research|June 3, 2021
Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical OutcomesDavid Price, Rupert Jones, Pascal Pfister, et al.
Chest|October 8, 2020
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment TrialNicola A Hanania, David M Mannino, Gerard J Criner, et al.
Respiratory Research|September 11, 2024
Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge SummaryWenying Lu, Rebekka Aarsand, Kerstin Schotte, et al.
Respiratory Medicine|December 5, 2022
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysisSamuel Bardsley, Gerard J Criner, David M G Halpin, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|November 18, 2021
Discordant diagnostic criteria for pneumonia in COPD trials: a reviewRobert A Wise, Mona Bafadhel, Courtney Crim, et al.
The New England Journal of Medicine|April 19, 2018
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPDDavid A Lipson, Frank Barnhart, Noushin Brealey, et al.
The Lancet. Respiratory Medicine|July 9, 2019
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trialSteven Pascoe, Neil Barnes, Guy Brusselle, et al.
American Journal of Respiratory and Critical Care Medicine|March 13, 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Courtney Crim, Gerard J Criner, et al.
Pageof 15